181 related articles for article (PubMed ID: 12749516)
1. Factors associated with hospitalization costs for patients with community-acquired pneumonia.
Merchant S; Mullins CD; Shih YC
Clin Ther; 2003 Feb; 25(2):593-610. PubMed ID: 12749516
[TBL] [Abstract][Full Text] [Related]
2. Treatment costs of community-acquired pneumonia in an employed population.
Colice GL; Morley MA; Asche C; Birnbaum HG
Chest; 2004 Jun; 125(6):2140-5. PubMed ID: 15189934
[TBL] [Abstract][Full Text] [Related]
3. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
[TBL] [Abstract][Full Text] [Related]
4. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis.
Rozenbaum MH; Mangen MJ; Huijts SM; van der Werf TS; Postma MJ
Vaccine; 2015 Jun; 33(28):3193-9. PubMed ID: 25981488
[TBL] [Abstract][Full Text] [Related]
5. Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.
Vissink CE; Huijts SM; de Wit GA; Bonten MJ; Mangen MJ
BMC Infect Dis; 2016 Sep; 16(1):466. PubMed ID: 27589847
[TBL] [Abstract][Full Text] [Related]
6. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity.
Cupurdija V; Lazic Z; Petrovic M; Mojsilovic S; Cekerevac I; Rancic N; Jakovljevic M
J Bras Pneumol; 2015; 41(1):48-57. PubMed ID: 25750674
[TBL] [Abstract][Full Text] [Related]
7. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia.
Egger ME; Myers JA; Arnold FW; Pass LA; Ramirez JA; Brock GN
BMC Med Inform Decis Mak; 2016 Mar; 16():34. PubMed ID: 26976388
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia.
Menéndez R; Reyes S; Martínez R; de la Cuadra P; Manuel Vallés J; Vallterra J
Eur Respir J; 2007 Apr; 29(4):751-6. PubMed ID: 17005580
[TBL] [Abstract][Full Text] [Related]
10. The cost of treating community-acquired pneumonia.
Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
Clin Ther; 1998; 20(4):820-37. PubMed ID: 9737840
[TBL] [Abstract][Full Text] [Related]
11. CAPECO: Cost evaluation of community acquired pneumonia managed in primary care.
Personne V; Chevalier J; Buffel du Vaure C; Partouche H; Gilberg S; de Pouvourville G
Vaccine; 2016 Apr; 34(19):2275-80. PubMed ID: 26979138
[TBL] [Abstract][Full Text] [Related]
12. Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort.
Wu JH; Howard DH; McGowan JE; Turpin RS; Henry Hu X
Clin Ther; 2006 Sep; 28(9):1451-61. PubMed ID: 17062317
[TBL] [Abstract][Full Text] [Related]
13. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
14. Burden of community-acquired pneumonia in North American adults.
File TM; Marrie TJ
Postgrad Med; 2010 Mar; 122(2):130-41. PubMed ID: 20203464
[TBL] [Abstract][Full Text] [Related]
15. The annual economic burden among patients hospitalized for community-acquired pneumonia (CAP): a retrospective US cohort study.
Divino V; Schranz J; Early M; Shah H; Jiang M; DeKoven M
Curr Med Res Opin; 2020 Jan; 36(1):151-160. PubMed ID: 31566005
[No Abstract] [Full Text] [Related]
16. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
Zhou QT; He B; Zhu H
Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
[TBL] [Abstract][Full Text] [Related]
17. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital.
Goss CH; Rubenfeld GD; Park DR; Sherbin VL; Goodman MS; Root RK
Chest; 2003 Dec; 124(6):2148-55. PubMed ID: 14665494
[TBL] [Abstract][Full Text] [Related]
18. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.
Sato R; Gomez Rey G; Nelson S; Pinsky B
Appl Health Econ Health Policy; 2013 Jun; 11(3):251-8. PubMed ID: 23605251
[TBL] [Abstract][Full Text] [Related]
20. Adherence to guidelines and its impact on outcomes in patients hospitalized with community-acquired pneumonia at a university hospital.
Silveira CD; Ferreira CS; Corrêa Rde A
J Bras Pneumol; 2012; 38(2):148-57. PubMed ID: 22576421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
